Inhibitory Proteins for 20S Proteasome Regulation as Cancer Treatment

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Proteasomal protein degradation is crucial in maintaining cellular integrity and in regulating key cellular processes including cell cycle, proliferation and cell death. The 20S proteasome can function as an independent degradation machinery and tight regulation must exist to control its proteolytic capacity. Despite the major importance of 20S proteasome regulation only a small number of regulators have been identified to date. Here, we discovered a novel family of inhibitory protein - CCRs (Catalytic Core Regulators) that specifically regulate the 20S proteasome, and not the 26S counterpart, and increase its effectiveness in cancer treatment.

Yeda

Background and Unmet Need

The protein degradation machinery plays a critical role in the maintenance of cellular homeostasis, preventing the accumulation of damaged or misfolded proteins and controlling the levels of regulatory proteins. Proteasomal degradation is mediated mainly by two proteasomal complexes: the 26S proteasome and the 20S proteasome which under oxidizing conditions is the major degradation machinery. While the presence of a regulatory mechanism to control this degradation process is highly likely, only two 20S proteasome regulators have been identified; NAD(P)H dehydrogenase [quinone] 1 (NQO1) and DJ-11.

The Solution

Prof. Michal Sharon and her team discovered a novel family of Catalytic Core Regulators (CCRs)2 that controls 20S proteasome-mediated degradation. These could be used for cancer therapy and treatment for diseases associated with proteasome dysfunction.

Technology Essence

The team performed a bioinformatic screen to identify other proteins with sequence and structural similarities to DJ-1 and NQO1. This led to the discovery of a family of 17 relatively small proteins of 20–30 kDa, named catalytic core regulators (CCRs), that oversee 20S proteasome activity. Of the 10 short-listed proteins that were identified and characterized, all were able to inhibit 20S proteasome degradation of known substrates, both in vitro and in cells. These protein regulators were able to specifically bind to the 20S proteasome, but not the 26S proteasome, and affect protein degradation. In addition, they demonstrate that the CCRs organize into a feed-forward regulatory circuit3 involving the master regulator of the oxidative stress response, Nrf2. Certain CCRs influence the stability of Nrf2, which subsequently upregulates the expression of other CCRs, leading to an overall dampening of 20S proteasome-mediated degradation of unfolded protein substrates within the cell. Figure 1: CCRs organize into a feed-forward regulatory loop with Nrf2 and the 20S proteasome.

Development Status

Prof. Sharon and her team found that CCRs bind the proteasome through an internal b-strand that is exposed upon
interaction with the 20S proteasome. Binding by the 20S proteasome is mediated by the b-strand rather than the aring, and specifically by the PSMB4 subunit. Moreover, they discovered that the interaction formed by PSMB4 and the CCR leads to allosteric inhibition of the proteasome’s three enzymatic activities. By dissecting the structural properties that are required for CCR-like function, the group could recapitulate the CCR activity using a designed artificial protein that is half the size of natural CCRs. This mean of 20S proteasome-specific attenuation opens avenues for decoupling the 20S and 26S proteasome degradation pathways for selective 20S proteasomeinhibitors for therapeutic applications.

References:

1. Moscovitz, O., Ben-Nissan, G., Fainer, I. et al. (2015). The Parkinson’s-associated protein DJ-1 regulates the
20S proteasome. Nat Commun 6, 6609 https://doi.org/10.1038/ncomms7609 [1]
2. Olshina, M. A., Arkind, G., Kumar Deshmukh, F., Fainer, I., Taranavsky, M., Hayat, D., Ben-Dor S., Ben-Nissan
G.,Sharon, M. (2020). Regulation of the 20S proteasome by a novel family of inhibitory proteins. Antioxidants &
redox signaling, 32(9), 636-655.?? https://doi.org/10.1089/ars.2019.7816 [2]
3. Mangan S, Alon U. (2003). Structure and function of the feedforward loop network motif. Proceedings of the
National Academy of Sciences, 100(21), 11980-11985. https://doi.org/10.1073/pnas.2133841100 [3]

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Clinical Research, Trials
  • Cytology, Cancerology, Oncology
  • Medical Research
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools

Yeda

Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide

Yeda

Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support